Serac Life Sciences’ Post

Our work with King's College London (KCL) School of Biomedical Engineering & Imaging Sciences to design machine learning approaches to evaluate imaging of patients with rheumatoid arthritis using maraciclatide is continuing to make good progress. Congratulations to our KCL colleagues Andrew Reader, Gary Cook and Robert Cobb who have had a paper on their ongoing research titled: “Improved Classification Learning from Highly Imbalanced Multi-Label Datasets of Inflamed Joints in ⁹⁹ᵐTc-Maraciclatide Imaging of Arthritic Patients by Natural Image and Diffusion Model Augmentation” accepted for presentation at the International Conference on Medical Image Computing and Computer Assisted Intervention (MICCAI Society) later this year. Maraciclatide is in development to diagnose and detect inflammation in patients with inflammatory arthritis and endometriosis. The development of AI tools could enhance the potential of maraciclatide as a new imaging marker. See more details here: https://lnkd.in/eUpdj33T Maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities. #molecularimaging #medicalimaging #AI #machinelearning #rheumatoidarthritis #endometriosis #nuclearmedicine #precisionmedicine #MICCAI2024